3Z-3-[(1H-pyrrol-2-yl)-methylidene]-1-(1-piperidinylmethyl)-2H-indol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3Z-3-[(1H-pyrrol-2-yl)-methylidene]-1-(1-piperidinylmethyl)-2H-indol-2-one
• 英文别名: 3Z-3-[(1H-pyrrol-2-yl)-methylidene]-1-(1-piperidinylmethyl)-1,3-2H-indol-2-one；Z24；1-piperidin-1-ylmethyl-3-(1-H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one；(3Z)-1-(piperidin-1-ylmethyl)-3-(1H-pyrrol-2-ylmethylidene)indol-2-one
• 化学式: C₁₉H₂₁N₃O
• 分子量: 307.395
• InChiKey: PRSUSVFFBBXWQI-LGMDPLHJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  39.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 Z-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one 在 哌啶 作用下， 以 乙醇 为溶剂， 反应 14.0h， 以77%的产率得到3Z-3-[(1H-pyrrol-2-yl)-methylidene]-1-(1-piperidinylmethyl)-2H-indol-2-one
  参考文献：
  名称：

  KINASE INHIBITORS FOR THE TREATMENT OF DISEASE

  摘要：

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调控、调节和/或抑制异常细胞增殖。

  公开号：

  US20040102509A1

文献信息

• Kinase inhibitors for the treatment of disease
  申请人：Allergan, Inc.

  公开号：US06699863B1

  公开（公告）日：2004-03-02

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调控、调节和/或抑制异常细胞增殖。
• COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT
  申请人：Friess Thomas

  公开号：US20090098118A1

  公开（公告）日：2009-04-16

  The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment) a type II anti-CD20 antibody and an anti-Bcl-2 active agent.
• Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent
  申请人：Friess Thomas

  公开号：US20110086025A1

  公开（公告）日：2011-04-14

  The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent.
• CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES
  申请人：Biokine Therapeutics Ltd.

  公开号：US20180221393A1

  公开（公告）日：2018-08-09

  A method of treating cancer in a subject is disclosed. The method comprises administering to the subject: (i) a therapeutically effective amount of an inhibitory agent that down-regulates an amount of a polypeptide selected from the group consisting of BCL-2, MCL-1 and cyclin D1; and (ii) a therapeutically effective amount of a CXCR4 binding agent that increases the expression of miR-15a and/or 16-1, thereby treating the cancer.
• [EN] CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES<br/>[FR] AGENTS DE LIAISON DE CXCR4 POUR LE TRAITEMENT DE MALADIES
  申请人：BIOKINE THERAPEUTICS LTD

  公开号：WO2017021963A1

  公开（公告）日：2017-02-09

  A method of treating cancer in a subject is disclosed. The method comprises administering to the subject: (i) a therapeutically effective amount of an inhibitory agent that down-regulates an amount of a polypeptide selected from the group consisting of BCL-2, MCL-1 and cyclin D1; and (ii) a therapeutically effective amount of a CXCR4 binding agent that increases the expression of mi R-15a and/or 16-1, thereby treating the cancer.